Eight Talking Points From ESMO
Seattle Genetics scores victory for mid-caps and more
Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.
You may also be interested in...
A first look at data from Merck & Co’s KEYNOTE-522 trial of Keytruda in early triple-negative breast cancer showed significant pathological response rates and hinted at good things to come in event-free survival, but experts at ESMO want more mature data.
The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.
Middling data for Roche’s IO plus chemo combo were presented at ESMO, while Seattle's rival drug antibody conjugate posted an impressive Phase I response rate.